Inflammatory bowel disease
Conditions
Interventions
Observation group of response and non-response to biological agents/targeted drugs:None
Sponsors
Hangzhou First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 - 75 years old, gender not restricted; 2. Clearly diagnosed with ulcerative colitis (UC) or Crohn's disease (CD), based on standard clinical, endoscopic and pathological criteria, with a disease duration of >= 3 months; 3. The disease is in an active stage: for UC patients, the Mayo score is >= 6 points (or the modified Mayo score is >= 5 points), for CD patients, the CDAI is >= 220 points; 4. Planning to initiate or switch to biologics (infliximab, adalimumab, vedolizumab, ustekinumab, etc.) or small molecule targeted drugs (tofacitinib, upadacitinib, etc.); 5. Agree to complete sample collection, endoscopic examination and clinical follow-up at the specified time points during the study; 6. Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Coexisting intestinal infections (such as Clostridium difficile, cytomegalovirus, Mycobacterium tuberculosis, etc.) or active systemic infections; 2. Previous history of malignant tumors (excluding non-melanoma skin cancer); 3. Pregnant or lactating women; 4. Complicated with severe heart, liver, or kidney dysfunction (ALT/AST > 3 times the upper limit of normal, eGFR < 30 mL/min); 5. Known to be allergic to the biological agents or targeted drug components involved in the study; 6. With ostomy or pouching; 7. Participated in other interventional clinical trials within 3 months before enrollment; 8. Other conditions judged by the investigator as unsuitable for enrollment (such as severe mental illness, history of drug abuse, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Multimodal sequencing results; | — |
Countries
China
Contacts
Public ContactWang zhijie
Hangzhou First People's Hospital
Outcome results
None listed